<DOC>
	<DOCNO>NCT00782093</DOCNO>
	<brief_summary>The objective study evaluate safety , tolerability , pharmacokinetic profile volociximab intravitreous injection subject subfoveal choroidal neovascularization secondary age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>A Phase 1 Ascending Parallel Group Trial Establish Safety , Tolerability Pharmacokinetics Profile Volociximab ( Alpha 5 Beta 1 Integrin Antagonist ) Subjects With Neovascular Age- Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subfoveal choroidal neovascularization ( CNV ) due AMD ( i.e. , predominantly classic , minimally classic occult classic ) document fluorescein angiogram . Any prior treatment AMD intravitreal treatment indication study eye prior screen visit , except oral supplement vitamins mineral . Previous concomitant therapy intravitreous corticosteroid . Any following underlying disease include : Diabetic retinopathy History evidence severe cardiac disease ( e.g. , NYHA Functional Class III IV see Appendix 19.6 ) , history clinical evidence unstable angina , acute coronary syndrome , myocardial infarction revascularization within last 6 month , ventricular tachyarrythmias require ongoing treatment . History evidence clinically significant peripheral vascular disease , intermittent claudication prior amputation . Clinically significant impaired renal ( serum creatinine &gt; 2.5 mg/dl s/p renal transplant receive dialysis ) hepatic function . Patients result outside range may enrol consultation Ophthotech . Stroke ( within 12 month trial entry ) . Any major surgical procedure within one month trial entry . Previous therapeutic radiation region study eye . Any treatment investigational agent past 60 day condition . Women pregnant nursing . Known serious allergy fluorescein dye use angiography , component ranibizumab formulation , component volociximab formulation .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>AMD</keyword>
</DOC>